Purdue Pharmaceuticals, L.P.
Headquarters
One Stamford Forum
Stamford
Connecticut
06901-3431
United States
Tel: 203-588-8000
Fax: 203-588-8850
Website: http://www.purduepharma.com/
About Purdue Pharmaceuticals, L.P.
Purdue Pharmaceuticals, L.P., headquartered in Stamford, CT, is a privately held pharmaceutical company founded by physicians and focused on meeting the needs of healthcare providers and the patients in their care. Together with its independent associated companies, Purdue is dedicated to finding, developing, and bringing to market new medicines and related products that improve health outcomes. The company has long been known for its pioneering research on persistent pain, a principal cause of human suffering.
Purdue also has a growing line of non-prescription products including laxatives, microbicides, and nutraceuticals. The company is dedicated to serving the evolving needs of healthcare providers, patients, and caregivers with prescription and non-prescription medicines. A commitment to innovation and caring spans every aspect of the organization, from discovering and launching new medicines to demonstrating their medical value.
Purdue has led the battle against inadequate treatment of pain by developing sustained-release medications to manage pain. Its sales, marketing, and medical education professionals provide the healthcare community with comprehensive educational materials and programs relating to pain management.
In 1993, Purdue established Partners Against Pain® as a resource to help patients, caregivers, and healthcare professionals advance standards of pain care and alleviate unnecessary suffering through education and advocacy. Purdue has also assumed a leading role in addressing the serious public health problem of prescription drug abuse, supporting programs intended to help stem abuse.
At its research facilities in Cranbury, New Jersey, Purdue scientists are discovering new compounds to treat pain and developing formulations and delivery systems to help improve patient safety.
231 articles about Purdue Pharmaceuticals, L.P.
-
Grünenthal Group and Purdue Pharma L.P. Enter Into a Licensing Agreement
5/28/2013
-
Bad Night: Purdue Pharma L.P. Axes 90 Reps of Transcept Pharmaceuticals, Inc. Sleep Drug
5/14/2013
-
Purdue Pharma L.P. to Present Review of Underlying Variability in Opioid Analgesic Conversion Recommendations at American Pain Society Annual Meeting
5/9/2013
-
ElMindA and Purdue Pharma L.P. Enter Research Agreement to Develop Novel Diagnostics to Improve Pain Management
1/29/2013
-
EMC Corporation Helps Purdue Pharma L.P. Transform IT
12/13/2012
-
Transcept Pharmaceuticals, Inc. Announces Broadened Intermezzo® Commercialization Strategy Including Initiation of a Direct to Consumer Advertising Campaign by Purdue Pharma L.P.
11/27/2012
-
NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
10/23/2012
-
Former Purdue Pharma L.P. Execs Lose Federal Appeal
7/30/2012
-
Purdue Pharma L.P. Ends Infinity Pharmaceuticals Inc. Partnership, Buys $27.5 Million in Stock
7/19/2012
-
Purdue Pharma L.P. Comments on FDA Announcement on REMS for Extended-Release and Long-Acting Opioid Analgesics
7/10/2012
-
OxyContin Maker, Purdue Pharma L.P., Guards Exclusivity
6/28/2012
-
Purdue Pharma L.P. to Present Data on Physician Understanding of the Risk Evaluation and Mitigation Strategy (REMS) for Butrans® (buprenorphine) Transdermal System CIII Data at International Society of Pharmacoeconomics and Outcomes Research Annual Meetin
6/5/2012
-
Purdue Pharma L.P. To Present Analysis Of Butrans(R) (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
5/18/2012
-
Purdue Pharma L.P. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo(R) (zolpidem tartrate) Sublingual Tablets CIV
5/8/2012
-
Purdue Pharma L.P.'s Intermezzo Rouses Drug Category With $100 Million Push
4/9/2012
-
Transcept Pharmaceuticals, Inc. Announces National Product Launch of Intermezzo(R) by Purdue Pharma L.P.
4/5/2012
-
Purdue Pharma L.P. Release: Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV Are Now Available for Insomnia Characterized by Middle-of-the-Night Awakenings Followed by Difficulty Returning to Sleep
4/5/2012
-
Purdue Pharma L.P. Release: Mayor Cornett Launches Campaign to Combat Prescription Medication Abuse Through Safe Storage and Disposal
2/28/2012
-
Unity Management Group Subsidiary Announces First Contracts of 2012 With Purdue Pharma L.P. and Novartis AG
1/26/2012
-
Transcept Pharmaceuticals, Inc. Receives $10 Million Milestone Payment from Purdue Pharma L.P. for Listing of Intermezzo Formulation Patents in FDA Orange Book
12/22/2011